Galsulfase

This enzyme replacement therapy provides the enzyme N-acetylgalactosamine-4-sulfatase that is deficient in patients with Maroteaux-Lamy syndrome, a rare inherited metabolic disorder. Regular infusions help break down the glycosaminoglycans that accumulate in tissues and cause progressive organ damage.

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Yes, Galsulfase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.